Current Edition

ability

New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients

Researchers from Samsung Medical Center and Guardant Health, Inc. have demonstrated the feasibility of determining a measure analogous to tumor mutation burden (TMB), a promising …

Continue Reading →
brain

Study: Brain Exercise Improves Brain Function in Retirement Community Population

A newly published study of older adults residing in assisted living and independent living communities shows significant improvement in brain processing speed among those who used a …

Continue Reading →
cash

After failure, Zynerba shifts gears to save cash

Zynerba Pharmaceuticals on Thursday announced negative topline results from a Phase 1 safety and dosing study of its transdermal tetrahydrocannabinol patch ZYN001, sending shares down …

Continue Reading →
Europe

Novo’s oral semaglutide outperforms Jardiance in late-stage study

Danish drugmaker Novo Nordisk said Tuesday its PIONEER 2 study testing oral semaglutide in patients with type 2 diabetes met its primary objective, showing a …

Continue Reading →
2nd

AstraZeneca won’t submit lung drug for COPD after 2nd study miss

AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the second of two Phase 3 …

Continue Reading →
Europe

Madrigal scores in mid-stage NASH study

Madrigal Pharmaceuticals on Thursday reported highly anticipated results for its Phase 2 non-alcoholic steatohepatitis (NASH) drug MGL-3196, unveiling positive data after 36 weeks. The study …

Continue Reading →
Europe

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

Pediatric Study Demonstrated Improvements in Rickets Severity, Growth, Pain and Physical Activity in Children with Debilitating, Lifelong Hereditary Disease Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Kyowa …

Continue Reading →
Arzerra

Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma

Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival Genmab A/S (Nasdaq Copenhagen: GEN) announced today that …

Continue Reading →
clinical

Rapid Medical initiates TIGER Clinical Study

Data from the study will be submitted to the FDA in support of Market Clearance for TIGERTRIEVER in the U.S. Rapid Medical, an Israeli company …

Continue Reading →
Asia Pacific

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)

Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy at 40 Weeks Ultragenyx Pharmaceutical …

Continue Reading →